INTRODUCTION {#s1}
============

Renal cell carcinoma (RCC) accounts for over 80% of kidney cancers, and 338,000 new cases were diagnosed worldwide in 2012 \[[@R1]\]. The incidence of RCC is increasing due to recent improvements in screening technologies, such as ultrasound and computed tomography. Although molecular-targeted anti-angiogenic multi-tyrosine kinase inhibitors have been developed, they show limited effects, particularly in patients with advanced RCC; consequently, the prognosis of advanced-stage RCC is still poor \[[@R2]\].

Sunitinib is one of the most common molecular-targeted drugs for metastatic RCC. A phase 3 clinical trial of sunitinib versus interferon alpha in patients with metastatic RCC ushered in the molecular-targeted era in the treatment of RCC \[[@R3]\]. Although side effects, such as hand-foot syndrome, thrombocytopenia, general fatigue, and hypothyroidism, often occur with sunitinib treatment, sunitinib is still a standard treatment for metastatic RCC due to the relatively longer progression-free survival time and higher response rate \[[@R4]--[@R6]\]. Additionally, sunitinib therapy is often associated with treatment failure in patients with metastatic RCC.

MicroRNAs (miRNAs) are small noncoding RNAs that function as a fine tuner of protein-coding or noncoding gene expression \[[@R7], [@R8]\]. A growing body of evidence suggests that aberrantly expressed miRNAs contribute to cancer pathogenesis and drug resistance \[[@R9], [@R10]\]. We have sequentially identified antitumor miRNA-mediated RCC pathways based on RCC miRNA signatures \[[@R11]--[@R13]\]. The next challenge in our RCC study is to identify key molecules and novel pathways involved in the resistance of molecular-targeted therapies for RCC.

Accordingly, in this study, we constructed a miRNA expression signature to identify pathways activated by sunitinib treatment using autopsy specimens from patients with RCC. The miRNA expression signature revealed that *microRNA-101*(*miR-101*) was significantly suppressed in sunitinib-treated RCC tissues compared with that in primary RCC tissues. Additionally, we demonstrated that *miR-101* exhibited antitumor activity and directly suppressed ubiquitin-like with PHD and ring finger domains 1 (*UHRF1*). Moreover, we investigated *UHRF1*-mediated downstream pathways in RCC cells. Elucidation of the miRNA signature of sunitinib-treated RCC tissues may be useful for identification of the novel molecular mechanisms of RCC recurrence, metastasis, and drug resistance.

RESULTS {#s2}
=======

Construction of the miRNA expression signature of sunitinib-treated RCC {#s2_1}
-----------------------------------------------------------------------

First, we analyzed the expression levels of mature miRNAs in sunitinib-treated RCC specimens by PCR- based array analysis. Also, we reviewed our miRNA expression data of 10 sunitinib-naïve RCC specimens and 5 normal kidney tissues, and we constructed a signature of downregulated miRNAs in sunitinib-naïve RCC tissues ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}). Of the 11 sunitinib- treated RCC specimens examined in this study, we used 4 specimens (No. 1, No. 5, No. 6, and No. 8; Table [1](#T1){ref-type="table"}) for array analysis. Compared with our previous miRNA signature in primary RCC specimens, 232 miRNAs were significantly downregulated in sunitinib-treated RCC specimens \[[@R11]\]. We listed the top 40 downregulated miRNAs in sunitinib-treated RCC specimens (Table [2](#T2){ref-type="table"}). Among them, we focused on *miR-101*, which showed the most dramatic downregulation in sunitinib-treated RCC, for further studies.

###### Patient characteristics (sunitinib-treated RCC specimens)

  Patient   Specimen No.   Location      Age (years)   stage at diagnosis   Histological type   Grade   Treatment   Treatment duration (months)                       Pathological feature of autopsy   survival from diagnosis (months)                                                                                                       
  --------- -------------- ------------- ------------- -------------------- ------------------- ------- ----------- ------------------------------------------------- --------------------------------- ---------------------------------- ----- --------------------------------------------------------------------------------------------- -----
  A         1              Kidney        69            4                    4                   2       1           Clear cell carcinoma                              3                                 Sunitinib, temsirolimus            8.5   Multiple lung metastasis Bone metastasis                                                      9.1
  2         Lymph node                                                                                                                                                                                                                                                                                                                         
  3         Liver                                                                                                                                                                                                                                                                                                                              
  4         Lung                                                                                                                                                                                                                                                                                                                               
  5         Tumor emboli                                                                                                                                                                                                                                                                                                                       
  B         6              Kidney        80            3                    3c                  0       0           Clear cell carcinoma                              3                                 Sunitinib                          0.7   IVC tumor emboli                                                                              1.8
  7         Kidney                                                                                                                                                                                                                                                                                                                             
  8         Tumor emboli                                                                                                                                                                                                                                                                                                                       
  C         9              Mesenterium   62            1                    1b                  0       0           Clear cell carcinomawith spindle cell carcinoma   3                                 Sunitinib, axitinib                34    Multible bone metastasis Pleural metastasis Lung metastasis Paraaorta lymph node metastasis   43
  10        Lymph node                                                                                                                                                                                                                                                                                                                         
  11        Pleura                                                                                                                                                                                                                                                                                                                             

###### Downregulated miRNAs in sunitinib-treated RCC (versus primary RCC)

  miRNA               Log2 ratio (sunitinib failure/primary)   Primary RCC   Sunitinib failure RCC   *P*-value
  ------------------- ---------------------------------------- ------------- ----------------------- -----------
  *hsa-miR-101*       --9.89                                   0.00193       2.04E-06                6.74E-05
  *hsa-miR-29b*       --9.73                                   0.00213       2.51E-06                6.20E-05
  *hsa-miR-190*       --9.66                                   0.00061       7.51E-07                6.39E-04
  *hsa-miR-128*       --9.46                                   0.00036       5.11E-07                2.52E-04
  *hsa-miR-23b*       --9.40                                   0.00035       5.11E-07                2.80E-03
  *hsa-miR-10b*       --9.36                                   0.00599       9.10E-06                3.84E-04
  *hsa-miR-766*       --9.27                                   0.00032       5.11E-07                1.75E-03
  *hsa-miR-142-5p*    --9.22                                   0.00035       5.92E-07                9.89E-04
  *hsa-miR-1275*      --9.03                                   0.00027       5.11E-07                2.17E-03
  *hsa-miR-629*       --8.99                                   0.00026       5.11E-07                3.24E-04
  *hsa-let-7c*        --8.91                                   0.00216       4.49E-06                3.73E-04
  *hsa-miR-135a*      --8.89                                   0.0006        1.26E-06                3.77E-02
  *hsa-miR-320b*      --8.84                                   0.00083       1.81E-06                7.83E-05
  *hsa-miR-24-2\**    --8.82                                   0.00023       5.11E-07                2.68E-04
  *hsa-miR-99a\**     --8.67                                   0.00035       8.60E-07                2.96E-04
  *hsa-miR-31\**      --8.59                                   0.00112       2.92E-06                4.68E-02
  *hsa-miR-450a*      --8.57                                   0.00019       5.11E-07                1.33E-03
  *hsa-miR-455-3p*    --8.49                                   0.00173       4.80E-06                5.45E-05
  *hsa-miR-340*       --8.43                                   0.00448       1.30E-05                6.99E-08
  *hsa-miR-126\**     --8.37                                   0.09059       2.75E-04                1.85E-04
  *hsa-miR-15b\**     --8.35                                   0.00017       5.11E-07                8.21E-03
  *hsa-miR-29c*       --8.32                                   0.03819       1.20E-04                1.13E-04
  *hsa-miR-204*       --8.29                                   0.03376       1.08E-04                6.10E-03
  *hsa-miR-424\**     --8.14                                   0.00014       5.11E-07                2.59E-03
  *hsa-miR-27b*       --8.13                                   0.00574       2.05E-05                2.67E-04
  *hsa-miR-1*         --8.08                                   0.00014       5.11E-07                5.84E-03
  *hsa-miR-592*       --8.05                                   0.00111       4.19E-06                2.77E-03
  *hsa-miR-20a\**     --7.97                                   0.0003        1.21E-06                4.21E-04
  *hsa-miR-450b-5p*   --7.85                                   0.00024       1.02E-06                1.48E-05
  *hsa-miR-10a*       --7.69                                   0.00458       2.22E-05                1.95E-04
  *hsa-let-7a*        --7.64                                   0.00517       2.60E-05                3.20E-06
  *hsa-miR-32*        --7.63                                   0.00014       7.23E-07                1.13E-04
  *hsa-miR-324-5p*    --7.63                                   0.00079       3.98E-06                1.07E-04
  *hsa-miR-429*       --7.63                                   0.0042        2.12E-05                5.17E-04
  *hsa-miR-98*        --7.61                                   0.00055       2.80E-06                1.39E-06
  *hsa-miR-598*       --7.59                                   0.00105       5.42E-06                5.39E-06
  *hsa-miR-148b*      --7.57                                   0.00042       2.20E-06                8.74E-07
  *hsa-miR-577*       --7.56                                   0.00021       1.11E-06                7.18E-03
  *hsa-miR-26b*       --7.51                                   0.05631       3.10E-04                3.85E-06
  *hsa-miR-545*       --7.48                                   0.00018       1.03E-06                3.89E-05

Expression levels of miR-101 in RCC clinical specimens and RCC cell lines {#s2_2}
-------------------------------------------------------------------------

Using RT-qPCR, we evaluated the expression levels of *miR-101* in normal kidney (*n* = 41), primary RCC (*n* = 42), and sunitinib-treated RCC (*n* = 11) tissues. Normal kidney tissues were adjacent to primary RCC tissues. The histological type of all primary RCC specimens was clear cell RCC, and 81.0% of patient tissues were classified as pT1 tumors according to the TNM classification (Table [3](#T3){ref-type="table"}).

###### Patient characteristics (primary RCC specimens)

  ---------------------------- ---- ----------
  Total number                 42   
  Median age (range) (years)   69   (41--91)
  Sex                               
   Male                        30   71%
   Female                      12   29%
  Laterality                        
   Right                       20   48%
   Left                        21   50%
   Bilateral                   1    2%
  Histology                         
   Clear cell RCC              42   100%
  Tumor grade                       
   G1                          5    12%
   G2                          29   69%
   G3                          7    2%
   Unknown                     1    2%
  Pathological tumor stage          
   pT1                         34   81%
   pT2                         1    2%
   pT3                         6    14%
   Unknown                     1    2%
  Metastasis                        
   M 0                         37   88%
   M 1                         5    12%
  Venous invasion                   
   v 0                         26   62%
   v 1                         15   36%
   Unknown                     1    2%
  Recurrence                        
   Recurrence +                3    7%
   Recurrence --               26   62%
   Unknown                     13   31%
  ---------------------------- ---- ----------

The expression levels of *miR-101* were significantly downregulated (*P* = 0.022) in primary RCC tissues compared with that in normal kidney tissues (Figure [1A](#F1){ref-type="fig"}). Furthermore, the levels of *miR-101* were significantly downregulated (*P* = 0.0013) in sunitinib-treated RCC tissues compared with those in normal kidney tissues (Figure [1A](#F1){ref-type="fig"}). *miR-101* expression levels were low in the RCC cell lines 786-O and Caki-1.

![Analysis of *miR-101* expression in RCC clinical specimens and functional analysis of *miR-101* transfection in 786-O and Caki-1 cells\
(**A**) Expression levels of *miR-101* in RCC clinical specimens. *RNU48* was used for normalization. (**B**) Cell proliferation was assessed 72 h after transfection with *miR-101* using XTT assays. (**C**) Cell migration was assessed 48 h after transfection with *miR-101* using uncoated Transwell polycarbonate membrane filters. (**D**) Cell invasion was assessed 48 h after transfection with *miR- 101* using Matrigel invasion assays. \**P*\< 0.0001. The bars indicate SDs.](oncotarget-07-59070-g001){#F1}

Effects of restoring miR-101 expression on cell proliferation, migration, and invasion in RCC cells {#s2_3}
---------------------------------------------------------------------------------------------------

To investigate the functional roles of *miR-101* in RCC, we performed gain-of-function studies in 786-O and Caki-1 cells by transfecting the cells with miRNA mimics.

XTT assays indicated that cell proliferation was inhibited by *miR-101* transfection in 786-O cells but not in Caki-1 cells (*P* \< 0.0001; Figure [1B](#F1){ref-type="fig"}). Using wound-healing assays, *miR-101* transfection significantly inhibited cell migration as compared with mock- or miR-control-transfected cells (*P* \< 0.0001; Figure [1C](#F1){ref-type="fig"}). Similarly, Matrigel invasion assays demonstrated that cell invasion activity was significantly inhibited in *miR-101* transfectants in comparison with mock or miR-control transfectants (*P* \< 0.0001; Figure [1D](#F1){ref-type="fig"}).

Identification of target genes suppressed by miR- 101 in RCC {#s2_4}
------------------------------------------------------------

To identify target genes of *miR-101*, we performed *in silico* analysis with the TargetScan program and GEO database. Analysis by the TargetScan program demonstrated that *miR-101* could target 3,013 genes according to the sequences of their 3′UTRs. Among these genes, 790 had broadly conserved *miR-101* sites across vertebrates. To gain further insights into which genes were suppressed by tumour-suppressive *miR-101* in RCC, we investigated their expression statuses in RCC clinical specimens and examined gene expression profiles in the GEO database (accession numbers: GSE36985 and GSE22541) to evaluate upregulated genes in RCC specimens. Consequently, among the 790 putative conserved target genes of *miR-101*, 43 genes were significantly upregulated in RCC specimens compared with those in normal kidney tissues (log~2~ ratio \> 1.0). We sorted these candidate genes in order of expression levels in RCC from the GEO database, because genes with high expression in RCC tissues are thought to function as oncogenes in RCC. Among genes which have conserved target sites for *miR-101*, *UHRF1* was the most upregulated gene. Among genes with multiple conserved target sites for *miR-101, EZH2* showed the greatest upregulation (Table [4](#T4){ref-type="table"}).

###### Putative target genes of *miR-101* and upregulated genes in RCC clinical specimens

  Entrez gene ID   Symbol       Location   Gene name                                                                                                   No. of conserved sites   No. of poorly conserved sites   GEO fold change
  ---------------- ------------ ---------- ----------------------------------------------------------------------------------------------------------- ------------------------ ------------------------------- -----------------
  29128            *UHRF1*      19p13.3    ubiquitin-like with PHD and ring finger domains 1                                                           1                        0                               3.178567
  8497             *PPFIA4*     1q32.1     protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4   1                        0                               3.09998
  1404             *HAPLN1*     5q14.3     hyaluronan and proteoglycan link protein 1                                                                  1                        0                               2.781324
  6664             *SOX11*      2p25.2     SRY (sex determining region Y)-box 11                                                                       1                        0                               2.577679
  163404           *LPPR5*      1p21.3     lipid phosphate phosphatase-related protein type 5                                                          1                        0                               2.450066
  2335             *FN1*        2q35       fibronectin 1                                                                                               1                        1                               2.446963
  23023            *TMCC1*      3q22.1     transmembrane and coiled-coil domain family 1                                                               1                        0                               2.226072
  286336           *FAM78A*     9q34.13    family with sequence similarity 78, member A                                                                1                        1                               2.194299
  2146             *EZH2*       7q36.1     enhancer of zeste homolog 2 (Drosophila)                                                                    2                        0                               2.003227
  5129             *CDK18*      1q32.1     cyclin-dependent kinase 18                                                                                  1                        0                               2.002138
  54541            *DDIT4*      10q22.1    DNA-damage-inducible transcript 4                                                                           1                        0                               1.998703
  55824            *PAG1*       8q21.13    phosphoprotein associated with glycosphingolipid microdomains 1                                             1                        0                               1.995799
  114088           *TRIM9*      14q22.1    tripartite motif containing 9                                                                               1                        0                               1.912238
  23452            *ANGPTL2*    9q33.3     angiopoietin-like 2                                                                                         1                        0                               1.707627
  3782             *KCNN3*      1q21.3     potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3                   2                        1                               1.643804
  10019            *SH2B3*      12q24.12   SH2B adaptor protein 3                                                                                      1                        0                               1.578665
  54329            *GPR85*      7q31.1     G protein-coupled receptor 85                                                                               1                        0                               1.54526
  84206            *MEX3B*      15q25.2    mex-3 homolog B (C. elegans)                                                                                1                        0                               1.526703
  50515            *CHST11*     12q23.3    carbohydrate (chondroitin 4) sulfotransferase 11                                                            1                        1                               1.521547
  2697             *GJA1*       6q22.31    gap junction protein, alpha 1, 43kDa                                                                        1                        0                               1.484238
  6925             *TCF4*       18q21.2    transcription factor 4                                                                                      2                        0                               1.474271
  60675            *PROK2*      3p13       prokineticin 2                                                                                              1                        0                               1.455421
  23551            *RASD2*      22q12.3    RASD family, member 2                                                                                       1                        0                               1.436602
  23151            *GRAMD4*     22q13.31   GRAM domain containing 4                                                                                    1                        0                               1.424502
  1003             *CDH5*       16q21      cadherin 5, type 2 (vascular endothelium)                                                                   1                        0                               1.387176
  4233             *MET*        7q31.2     met proto-oncogene (hepatocyte growth factor receptor)                                                      1                        0                               1.35197
  2313             *FLI1*       11q24.3    Friend leukemia virus integration 1                                                                         1                        0                               1.324487
  7039             *TGFA*       2p13.3     transforming growth factor, alpha                                                                           1                        0                               1.320208
  2113             *ETS1*       11q24.3    v-ets erythroblastosis virus E26 oncogene homolog 1 (avian)                                                 1                        0                               1.319352
  64919            *BCL11B*     14q32.2    B-cell CLL/lymphoma 11B (zinc finger protein)                                                               1                        0                               1.312486
  491              *ATP2B2*     3p25.3     ATPase, Ca++ transporting, plasma membrane 2                                                                2                        0                               1.306825
  3832             *KIF11*      10q23.33   kinesin family member 11                                                                                    1                        0                               1.299276
  114800           *CCDC85A*    2p16.1     coiled-coil domain containing 85A                                                                           1                        0                               1.22271
  111              *ADCY5*      3q21.1     adenylate cyclase 5                                                                                         1                        0                               1.214093
  80149            *ZC3H12A*    1p34.3     zinc finger CCCH-type containing 12A                                                                        1                        0                               1.203416
  50807            *ASAP1*      8q24.21    ArfGAP with SH3 domain, ankyrin repeat and PH domain 1                                                      1                        1                               1.145483
  2200             *FBN1*       15q21.1    fibrillin 1                                                                                                 1                        0                               1.11977
  54877            *ZCCHC2*     18q21.33   zinc finger, CCHC domain containing 2                                                                       1                        0                               1.118277
  861              *RUNX1*      21q22.12   runt-related transcription factor 1                                                                         2                        0                               1.105534
  84627            *ZNF469*     16q24.2    zinc finger protein 469                                                                                     1                        0                               1.100592
  80727            *TTYH3*      7p22.3     tweety homolog 3 (Drosophila)                                                                               1                        0                               1.096306
  23295            *MGRN1*      16p13.3    mahogunin, ring finger 1                                                                                    1                        0                               1.030189
  162073           *ITPRIPL2*   16p12.3    inositol 1,4,5-trisphosphate receptor interacting protein-like 2                                            1                        1                               1.024236

Thus, we focused on *UHRF1* and *EZH2* for further studies. Our strategy for selection of *miR-101*-targeted genes is shown in Figure [2](#F2){ref-type="fig"}.

![Selection strategy for target genes of *miR-101.*\
Analysis using the TargetScan program showed that 3,013 genes had putative target sites for *miR-101* in their 3′ UTRs. Among these genes, 790 had conserved target sites among vertebrates for *miR-101*. Then, we assessed the expression levels of these genes in RCC clinical specimens using GEO expression profiles (GSE36985 and GSE22541). Finally, genes upregulated in RCC (log~2~ ratio \> 1.0) were selected as putative target genes.](oncotarget-07-59070-g002){#F2}

UHRF1 and EZH2 were downregulated by miR- 101 transfection in RCC cells {#s2_5}
-----------------------------------------------------------------------

Next, we performed real-time RT-qPCR in 786- O and Caki-1 cells to analyze whether restoration of *miR- 101* altered the expression levels of the *UHRF1* and *EZH2* genes. Additionally, western blotting was carried out to investigate the effects of *miR-101* transfection on UHRF1 and EZH2 protein. The mRNA and protein expression levels of UHRF1 and EZH2 were significantly downregulated by *miR-101* transfection as compared with those in mock- or miR-control-transfected cells (*P* \< 0.002 and *P* \< 0.005; Figure [3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}, Figure [4A](#F4){ref-type="fig"} and [4B](#F4){ref-type="fig"}). Because direct regulation of *EZH2* by *miR-101* in RCC has been reported by several groups \[[@R14], [@R15]\], we focused on the *UHRF1* gene in this study.

![*miR-101* directly downregulated UHRF1 expression in RCC cells\
(**A**) *UHRF1* mRNA expression 72 h after transfection with *miR-101*. *GUSB* was used as an internal control. (**B**) UHRF1 protein expression 72 h after transfection with *miR-101*. GAPDH was used as a loading control. (**C**) *miR-101* binding sites in *UHRF1* mRNA. Luciferase reporter assays were carried out using a vector encoding the putative *miR-101* target site in the *UHRF1* 3′-UTR (position 1030--1036) for wild-type and deletion constructs. \**P* \< 0.002, \*\**P* \< 0.0001. The bars indicate SDs.](oncotarget-07-59070-g003){#F3}

![Effects of *miR-101* transfection on EZH2 mRNA and protein expression in RCC cells\
(**A**) *EZH2* mRNA expression was determined at 72 h after transfection with *miR-101*. *GUSB* was used as an internal control. (**B**) EZH2 protein expression was evaluated by western blotting at 72 h after transfection with *miR-101*. GAPDH was used as a loading control. \**P* \< 0.005. The bars indicate SDs.](oncotarget-07-59070-g004){#F4}

miR-101 directly suppressed UHRF1 in RCC cells {#s2_6}
----------------------------------------------

We performed luciferase reporter assays in 786- O cells to determine whether *UHRF1* was directly suppressed by *miR-101*. The TargetScan database predicted that the putative *miR-101* target site in *UHRF1* was position 1030--1036 in the 3′UTR. We used two vectors: a vector encoding a partial wild-type sequence of the 3′ UTR of *UHRF1* mRNA including the predicted *miR-101* target site, and a vector lacking the *miR-101* target site. We found that the luminescence intensity was significantly reduced by cotransfection with *miR-101* and the vector carrying the wild-type 3′UTR of *UHRF1*. However, the luminescence intensity was not decreased when the seed sequence of the target site was deleted from the vectors (*P* \< 0.0001; Figure [3C](#F3){ref-type="fig"}).

Knockdown of UHRF1 significantly inhibited cell proliferation, migration, and invasion in RCC cell lines {#s2_7}
--------------------------------------------------------------------------------------------------------

To investigate the functional role of *UHRF1* in RCC, we carried out loss-of-function studies by siRNA transfection. First, we evaluated the knockdown efficiency of si-*UHRF1* transfection in 786-O and Caki- 1 cells. RT-qPCR and western blotting indicated that si- *UHRF1* transfection effectively downregulated *UHRF1* and UHRF1 in 786-O and Caki-1 cells (*P* \< 0.0001; Figure [5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}).

![Effects of *UHRF1* knockdown in RCC cells and impact of UHRF1 expression on clinical RCC specimens\
(**A**) *UHRF1* mRNA expression was determined at 72 h after transfection with *si-UHRF1*. *GUSB* was used as an internal control. (**B**) UHRF1 protein expression was evaluated by western blotting at 72 h after transfection with *si-UHRF1*. GAPDH was used as a loading control. \**P* \< 0.0001. The bars indicate SDs. (**C**) Cell proliferation was assessed 72 h after transfection with *si-UHRF1* using XTT assays. (**D**) Cell migration was assessed 48 h after transfection with *si-UHRF1* using uncoated Transwell polycarbonate membrane filters. (**E**) Cell invasion was assessed 48 h after transfection with *si-UHRF1* using Matrigel invasion assays. \**P* \< 0.0001. The bars indicate SDs.](oncotarget-07-59070-g005){#F5}

In functional assays, si-*UHRF1* transfection significantly inhibited cell proliferation compared with that in mock- or si-control-transfected 786-O and Caki- 1 cells. Furthermore, cell migration and invasion were significantly inhibited by *si-UHRF1* transfection compared with mock- or si-control-transfection in 786-O and Caki-1 cells (*P* \< 0.0001; Figure [5C--5E](#F5){ref-type="fig"}).

Identification of pathways suppressed by UHRF1 knockdown in RCC cells {#s2_8}
---------------------------------------------------------------------

To further investigate which genes and pathways are suppressed by *miR-101/UHRF1* signaling, we performed genome wide gene expression analysis using knockdown of *UHRF1* by siRNA in 786-O cells. We deposited these data in the GEO (accession number: GSE77790). Genes which were significantly downregulated by *si-UHRF1* (Log2 \[si-UHRF1/mock\] \< --1.0) were categorized by KEGG pathway analysis using the GeneCodis program. Table [5](#T5){ref-type="table"} shows pathways that were significantly downregulated by knockdown of *UHRF1*. Pathways related to post-transcriptional modification, including the nucleotide excision repair and mismatch repair pathways, were significantly suppressed by knockdown of *UHRF1*.

###### Significantly downregulated pathways by knockdown of *UHRF1* in 786-O cells

  KEGG number   Pathways                                           *p* value   Genes
  ------------- -------------------------------------------------- ----------- ----------------------------------------------------------------------------------------------------------------------------------
  4110          Cell cycle                                         1.20.E-14   *SMC1A, PTTG2, MCM4, CDC20, CCNA2, PTTG1, MCM7, CDC25C, CCNB1, MAD2L1, PRKDC, SKP1, MCM3, DBF4, STAG2, BUB1B, CDC45, MCM2, CDK1*
  3030          DNA replication                                    3.77.E-11   *MCM4, MCM7, RFC1, POLD1, RFC5, MCM3, POLA2, FEN1, MCM2, RFC4*
  4114          Oocyte meiosis                                     4.72.E-07   *CALML3, SMC1A, PTTG2, CDC20, PTTG1, CDC25C, CCNB1, MAD2L1, SKP1, CALM3, CDK1*
  3018          RNA degradation                                    4.12.E-06   *DCPS, SKIV2L2, EXOSC3, PABPC1, PABPC3, LSM5, MPHOSPH6, DDX6*
  3430          Mismatch repair                                    1.48.E-05   *RFC1, POLD1, EXO1, RFC5, RFC4*
  5322          Systemic lupus erythematosus                       3.52.E-05   *HIST1H2AI, SSB, H2AFX, HIST1H2AJ, HIST1H2AC, HIST1H4D, HIST1H3G, SNRPD1*
  3013          RNA transport                                      4.26.E-05   *EIF5B, PABPC1, EIF3D, PABPC3, TACC3, EIF1AY, EIF3A, NUP205, EIF2S2, EIF1AX*
  3420          Nucleotide excision repair                         2.68.E-04   *CUL4B, RFC1, POLD1, RFC5, RFC4*
  5130          Pathogenic *Escherichia coli* infection            9.75.E-04   *CLDN1, NCK2, TUBA1B, ITGB1, NCL*
  533           Glycosaminoglycan biosynthesis - keratan sulfate   1.12.E-03   *CHST1, FUT8, B4GALT1*
  4914          Progesterone-mediated oocyte maturation            1.38.E-03   *CCNA2, CDC25C, CCNB1, MAD2L1, HSP90AA1, CDK1*
  4120          Ubiquitin mediated proteolysis                     3.11.E-03   *CDC20, CUL4B, UBE3B, UBE3A, BRCA1, TRIP12, SKP1*

UHRF1 and EZH2 expression in sunitinib-treated clinical RCC specimens {#s2_9}
---------------------------------------------------------------------

Finally, we examined UHRF1 expression status in clinical RCC specimens.

In a study with a relatively large sample size in GSE65615, higher *UHRF1* expression was observed in sunitinib-treated RCC specimens compared with that in sunitinib-naïve RCC specimens (*P* = 0.0049; Figure [6A](#F6){ref-type="fig"}). To examine whether *UHRF1* expression predicted overall survival, we used the TCGA-KIRC database (<https://tcga-data.nci.nih.gov/tcga/>). A total of 533 patients who underwent surgery for RCC and were pathologically diagnosed as having clear cell RCC were divided into two groups: z-score \> 0 and z-score \< 0 \[[@R16], [@R17]\]. Higher expression of *UHRF1* was associated with shorter overall survival (*P* \< 0.0001; Figure [6B](#F6){ref-type="fig"}). Multivariate Cox proportional hazards models were used to assess independent predictors of overall survival times, including disease stage, pT stage, age at diagnosis, gender, and *UHRF1* expression. High *UHRF1* expression was one of the significant prognostic factors in patients with RCC (hazard ratio = 2.027, 95% confidence interval = 1.490-- 2.759, *P* \< 0.0001; Figure [6C](#F6){ref-type="fig"}). To analyze UHRF1 protein expression, immunohistochemistry was performed with sunitinib-treated specimens. Immunohistochemical staining of UHRF1 in these specimens demonstrated high expression of UHRF1 in sunitinib-treated RCC cells (Figure [6D](#F6){ref-type="fig"}).

![Clinical significance of *UHRF1* expression in RCC\
(**A**) *UHRF1* was highly expressed in sunitinib-treated RCC compared with that in sunitinib-naïve RCC (*P* = 0.0049). (**B**) The overall survival rate of patients with high *UHRF1* expression was significantly lower than that of patients with low *UHRF1* expression (*P* \< 0.0001). (**C**) Multivariate Cox proportional hazards model for prediction of overall survival showed high *UHRF1* expression, advanced disease stage, and age at diagnosis were significant prognostic factors (*P* \< 0.0001, *P* \< 0.0001, *P* = 0.0005, respectively). (**D**) High expression of UHRF1 was observed in sunitinib-treated RCC specimens.](oncotarget-07-59070-g006){#F6}

Similarly, we analyzed *EZH2* status in clinical specimens. In GSE65615, we did not find significant difference of *EZH2* expression between sunitinib-treated RCC specimens and sunitinib-naïve RCC specimens (Figure [7A](#F7){ref-type="fig"}). Higher expression of *EZH2* was associated with shorter overall survival (*P* \< 0.0001; Figure [7B](#F7){ref-type="fig"}). High *EZH2* expression was one of the significant prognostic factors in patients with RCC (hazard ratio = 1.828, 95% confidence interval = 1.348--2.493, *P* \< 0.0001; Figure [7C](#F7){ref-type="fig"}). High expression of EZH2 was observed in several sunitinib-treated RCC specimens (Figure [7D](#F7){ref-type="fig"}).

![Clinical significance of *EZH2* expression in RCC\
(**A**) There was no significant difference of *EZH2* expression between sunitinib-treated RCC specimens and sunitinib-naïve RCC specimens. (**B**) The overall survival rate of patients with high *EZH2* expression was significantly lower than that of patients with low *EZH2* expression (*P* \< 0.0001). (**C**) Multivariate Cox proportional hazards model for prediction of overall survival showed high *EZH2* expression, advanced disease stage, and age at diagnosis were significant prognostic factors (*P* \< 0.0001, *P* \< 0.0001, *P* = 0.0013, respectively). (**D**) High expression of EZH2 was observed in several sunitinib-treated RCC specimens.](oncotarget-07-59070-g007){#F7}

DISCUSSION {#s3}
==========

In patients treated with sunitinib, the initial response rate is approximately 40%; however, sunitinib-treated RCC cells usually acquire resistance to tyrosine kinase inhibitors \[[@R18]\]. Thus, overcoming sunitinib resistance is a major challenge for medical oncologists and urologists. Some mechanisms for sunitinib resistance in RCC have been described. One of the most well-studied pathways is hypoxia. VEGF-targeted drugs (e.g., sunitinib, pazopanib, axitinib, etc.) promote hypoxia in tumors by inhibiting angiogenesis, leading to high expression of HIF proteins \[[@R19]\]. Consequently, HIF proteins bind to hypoxia-responsive elements (HRE) and promote the expression of multiple oncogenes \[[@R20], [@R21]\]. Another mechanism is the activation of alternative signaling pathways. Hepatocyte growth factor (HGF)/cMET signaling, sphingosine kinase 1 (SPHK1)/sphingosine-1-phosphate (S1P)/extracellular signal-regulated kinase (ERK) signaling, and delta-like ligand4 (DLL4)/Notch signaling have significant roles in drug resistance \[[@R22]--[@R24]\].

Our research group has sequentially identified novel RCC oncogenic pathways based on antitumor miRNAs identified using RCC miRNA signatures \[[@R11], [@R13], [@R25], [@R26]\]. Our miRNA-mediated RNA network analysis may provide many insights into RCC pathogenesis. In this study, we constructed a miRNA expression signature using autopsy specimens from patients with RCC who showed sunitinib failure. We believe that this miRNA signature will contribute to analysis of the mechanisms mediating resistance to sunitinib treatment. We identified 40 microRNAs that were downregulated in sunitinib-treated RCC tissues compared with that in untreated RCC tissues. Among these downregulated miRNAs, we identified *miR-29b*, which has been reported to suppress the extracellular matrix (ECM). In RCC cells, *miR-29b* directly suppresses the lysyl oxidase-like 2 (LOXL2) gene, leading to inhibition of cancer cell invasion \[[@R25]\]. Furthermore, *miR-23b*, *miR- 10b*,*miR-135a*, *miR-29c*, *miR-27b*, *miR-1*, and *miR- 26b* have been reported as tumour-suppressive miRNAs in RCC by different research groups \[[@R12], [@R26]--[@R30]\]. In particular, *let-7c* sensitizes cells to 5-FU in RCC cells *in vitro*, and *miR-27b* sensitizes cells to doxorubicin, sorafenib, gefitinib in RCC cells \[[@R31], [@R32]\]. Chemoresistance and miRNAs listed in this signature have been reported previously in a variety of cancers: *miR-29b* in ovarian cancer, *miR-128* in breast cancer, *miR-23b* in gastric cancer, and *miR-10b* in colorectal and breast cancer \[[@R33]--[@R36]\]. Therefore, miRNAs listed in this signature would have importance in resistance to both chemotherapy and molecular targeted therapy. These facts ensure the reliability of the data in this signature.

In this study, we focused on the *miR-101* because *miR-101* was the most strongly downregulated miRNA in sunitinib-treated tissues. Our present data showed that *miR-101* functioned as an antitumor miRNA in RCC cells. The antitumor roles of *miR-101* have been reported in various types of cancers, including hepatocellular carcinoma, gastric cancer, breast cancer, and lung cancer \[[@R37]--[@R40]\]. Furthermore, *miR-101* restoration enhances chemosensitivity in lung cancer and salivary gland adenoid cystic carcinoma \[[@R41], [@R42]\]. Thus, our data are consistent with previous studies of *miR-101* in cancer research.

One interesting capacity of miRNA analyses is identification of miRNA-regulated genes in the human genome and investigation of the functional roles of these miRNA-regulated genes in cancer cells. In this study, we found that *UHRF1*, the master regulator of epigenetic modifications, was directly suppressed by *miR-101* in RCC cells and that its expression enhanced cancer cell migration and invasion. Moreover, overexpression of UHRF1 was confirmed in sunitinib-treated RCC tissues, and higher expression of *UHRF1* was associated with shorter overall survival after surgery for RCC. Because sunitinib is the first-line treatment option for recurrent RCC after surgical treatment, this association is consistent with other results. Ablation of *UHRF1* induces genomic hypomethylation, and overexpression of *UHRF1* has been reported in several cancers \[[@R43], [@R44]\]. UHRF1 consists of five recognizable domains: PHD, Tudor, SRA, RING, and UBL \[[@R45]\]. UHRF1 is required for DNA methyltransferase 1 (DNMT1) function through direct binding to DNMT1 and activation of DNMT1 function for maintenance of DNA methylation \[[@R46]\].

We found that *miR-101* directly suppressed *UHRF1*; however, previous reports have indicated that *EZH2* is also directly suppressed by *miR-101* \[[@R14], [@R47]\]. Consistent with this, we confirmed that EZH2 was suppressed by *miR-101* in RCC cells (Figure [4](#F4){ref-type="fig"}). Interestingly, EZH2 has also been reported to be a master regulator of transcription by modulation of histone modification or methylation \[[@R48], [@R49]\]. *miR-101* can target and suppress both *UHRF1* and *EZH2* in RCC cells. Previous report indicated that *UHRF1* and *EZH2* synergistically and independently silence tumor suppressors by methylation: *UHRF1* induce methylation of tumor suppressor gene DNA CpGs and H3-K9me3, and *EZH2* induce methylation of H3-K27 \[[@R50]\]. Overexpression of both *UHRF1* and *EZH2* coordinately suppressed antitumor genes and contributed to prostate cancer pathogenesis and metastasis \[[@R50]\]. More recently, patient-derived clear cell RCC xenografts with sunitinib resistant phenotype showed increased EZH2 expression, and inhibition of *EZH2* resulted in enhancement of the antitumor effects of sunitinib \[[@R51]\]. Consequently, we speculate that overexpression of *UHRF1* and *EZH2* coordinately suppressed antitumor genes and deeply contribute to sunitinib resistant processes in RCC cells. In sunitinib-treated RCC tissues, loss of antitumor *miR- 101* may lead to upregulation of *UHRF1* and *EZH2*, and consequently, post-transcriptional modification of multiple genes would promote cancer-related phenotypes in cells. Moreover, we investigated the downstream pathways suppressed by knockdown of *UHRF1* and found that pathways such as cell cycle, DNA replication, and RNA degradation were enriched in RCC cells. Thus, antitumor *miR-101*-mediated *UHRF1* pathways may be suppressed by sunitinib treatment. Our present data will contribute to our understanding of drug-resistance mechanisms in RCC cells.

MATERIALS AND METHODS {#s4}
=====================

Patients and clinical RCC specimens {#s4_1}
-----------------------------------

Clinical kidney specimens were obtained from patients admitted to Kagoshima University Hospital and Teikyo University Chiba Medical Centre Hospital from 2004 to 2014. A total of 42 pairs of clear cell renal carcinoma and adjacent noncancerous tissue were obtained by nephrectomy. Three patients who died of RCC after sunitinib treatment failure underwent autopsies. RCC tissues (*n* = 42), adjacent noncancerous kidney tissues (*n* = 41), and sunitinib-treated RCC tissues (*n*= 11) were used. The patients\' backgrounds and characteristics are summarized in Tables [1](#T1){ref-type="table"} and [3](#T3){ref-type="table"}. Samples were staged according to the UICC TNM classification. Written consent for tissue donation for research purposes was obtained from each patient before sample collection. The protocol was approved by the Institutional Review Board of Chiba University, Kagoshima University and Teikyo University.

Construction of the miRNA expression signature of sunitinib-treated RCC {#s4_2}
-----------------------------------------------------------------------

miRNA expression patterns were evaluated using a TaqMan LDA Human microRNA Panel v2.0 (Applied Biosystems, Foster City, CA, USA). A cut-off *P*-value of less than 0.05 was used to narrow down the candidates after global normalization of the raw data. After global normalization, additional normalization was carried out with the *U6* gene. The procedure was performed as described previously \[[@R11], [@R52]\].

Cell culture {#s4_3}
------------

Human RCC cell lines (786-O and Caki-1 cells) were obtained from the American Type Culture Collection (Manassas, VA, USA). Cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum in a humidified atmosphere containing 5% CO~2~ and 95% air at 37°C.

RNA isolation {#s4_4}
-------------

Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The quality of RNA was confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies) as described previously \[[@R52]--[@R54]\].

Quantitative real-time reverse transcription polymerase chain reaction (RT-qPCR) {#s4_5}
--------------------------------------------------------------------------------

The expression levels of *miR-101* (Assay ID: 002253) were analyzed by TaqMan RT-qPCR (TaqMan MicroRNA Assay; Applied Biosystems) and normalized to *RNU48* expression (Assay ID: 001006). TaqMan probes and primers for *UHRF1*(P/N: Hs01086727_m1), *EZH2* (P/N: Hs01016789_m1), and *GAPDH* (P/N: Hs02758991_g1) as an internal control were obtained from Applied Biosystems (Assay-On-Demand Gene Expression Products). The procedure was carried out as previously described \[[@R52], [@R53]\].

Transfection with miRNA mimic and small-interfering RNA (siRNA) {#s4_6}
---------------------------------------------------------------

Ambion Pre-miR miRNA precursor for *hsa-miR-101-3p* (product ID: PM11414) was used in this study as a miRNA mimic. The following siRNAs were used: Stealth Select RNAi siRNA; si-*UHRF1* (cat no.: HSS179005 and HSS179006; Invitrogen); and negative control miRNA/siRNA (P/N: AM17110; Applied Biosystems). RNAs were incubated with OPTI-MEM (Invitrogen) and Lipofectamine RNAiMAX reagent (Invitrogen). The transfection procedures were performed as previously described \[[@R52], [@R53]\].

Cell proliferation, migration, and invasion assays {#s4_7}
--------------------------------------------------

Cell proliferation assays were performed using XTT assays, migration assays were performed using uncoated Transwell polycarbonate membrane filters, and invasion assays were performed using Matrigel-coated Boyden chambers, as previously described \[[@R52], [@R53]\].

Identification of genes suppressed by miR-101 {#s4_8}
---------------------------------------------

A combination of *in silico* and genome-wide gene expression analyses were carried out to investigate target genes suppressed by miR-101. First, genes suppressed by *miR-101* were listed using the TargetScan database. Next, to identify upregulated genes in RCC, we analyzed a publicly available gene expression data set in the Gene Expression Omnibus (GEO; accession numbers: GSE36985 and GSE22541). Finally, upregulated mRNAs containing *miR- 101* target sites were listed as putative target genes of *miR-101*. The procedure for selection is summarized in Figure [2](#F2){ref-type="fig"}.

Western blotting {#s4_9}
----------------

Immunoblotting was performed with rabbit anti-UHRF1 antibodies (1:1000, PA5-29884; Pierce Antibodies, Thermo Scientific, Fremont, CA, USA) and anti-EZH2 antibodies (1:250, 36-6300; Life Technologies, Carlsbad, CA, USA). Anti-GAPDH antibodies (1:1000, ab8245; Abcam, Cambridge, UK) were used as an internal loading control. Membranes were washed and incubated with anti-rabbit IgG horseradish peroxidase (HRP)-linked antibodies (7074; Cell Signaling Technology, Danvers, MA, USA). Complexes were visualized with Clarity Western ECL Substrate (Bio-Rad, Hercules, CA, USA). The procedures were performed as previously described \[[@R52], [@R53]\].

Plasmid construction and dual-luciferase reporter assay {#s4_10}
-------------------------------------------------------

Partial wild-type sequences of the *UHRF1* 3′ untranslated region (UTR) or those with a deleted *miR-101* target site (position 1030--1036 of the *UHRF1* 3′ UTR) were inserted between the *Xho*I--*Pme*I restriction sites in the 3′ UTR of the *hRluc* gene in the psiCHECK-2 vector (C8021; Promega, Madison, WI, USA). The protocol for vector construction was described previously \[[@R52], [@R53]\].

Identification of pathways and genes suppressed by UHRF1 in RCC {#s4_11}
---------------------------------------------------------------

To identify molecular pathways suppressed by *UHRF1* gene expression in RCC cells, we performed gene expression analysis using si-*UHRF1*-transfected 786-O cells. An oligomicroarray (SurePrint G3 Human 8×60k v3; Agilent Technologies) was used for gene expression studies. The data were deposited in the GEO database (accession number GSE77790). Genes downregulated by knockdown of UHRF1 were categorized into Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways using the GENECODIS program (<http://genecodis.cnb.csic.es/>). The strategy of this analysis procedure has been described previously \[[@R52]--[@R54]\].

Immunohistochemisty {#s4_12}
-------------------

A total of 11 specimens were used (Table [1](#T1){ref-type="table"}). Tissue specimens were immunostained with an Ultra-Vision Detection System (Thermo Scientific) following the manufacturer\'s protocol. Primary rabbit polyclonal antibodies against UHRF1 (1:500, PA5-29884; Pierce Antibodies, Thermo Scientific) and EZH2 (1:125, 36-6300; Life Technologies) were used for immunochemistry. The slides were treated with biotinylated goat antibodies (Histofine SAB-PO kit; Nichirei, Tokyo, Japan). The procedures were performed as previously described \[[@R52]--[@R54]\].

TCGA-KIRC and other human RCC data analysis {#s4_13}
-------------------------------------------

To explore the clinical significance of *UHRF1* in RCC, we used the RNA sequencing database in TCGA-KIRC (The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma: <https://tcga-data.nci.nih.gov/tcga/>). The gene expression and clinical data were retrieved from cBioportal (<http://www.cbioportal.org/>, the provisional data downloaded on May 10th, 2016). The normalized mRNA expression value in the RNA sequencing data was processed and provided in Z-score. We performed multivariate analysis (Cox proportional hazards model) that included pathological tumour and disease stage, age, and gender under consideration. We also employed the gene expression microarray data including sunitinib-treated and sunitinib-naïve human RCC specimens (GSE 65615).

Statistical analysis {#s4_14}
--------------------

The relationships between 2 groups and numerical values were analyzed using Mann-Whitney *U*-tests. The relationships among more than 3 variables and numerical values were analyzed using the Bonferroni-adjusted Mann-Whitney *U*-test. A multivariate Cox proportional hazards model was used to establish independent factors for overall survival. Survival analysis was carried out using the Kaplan--Meier method and log-rank tests. The Kaplan--Meier method and log-rank test were performed using JMP software (version 12, SAS Institute Inc., Cary, NC, USA); all other analyses were performed using Expert StatView (version 5, SAS Institute Inc.).
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